The radiosensitizing effects of a STAT3/HDAC dual-target inhibitor derived from isoalantolactone in solid tumor models
Abstract Multi-target combination therapy has emerged as a promising anti-cancer strategy. STAT3 and HDAC are key contributors to tumorigenesis and progression. We previously reported the design of a novel dual-target inhibitor of STAT3 and HDAC (named mhl-28), which was developed by employing a nat...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
BMC
2026-03-01
|
| Цуврал: | BMC Cancer |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://doi.org/10.1186/s12885-026-15816-7 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
